Magnolia Medical Technologies, Inc., announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC),
| SEATTLE, Dec. 15, 2021 /PRNewswire/ -- Magnolia Medical Technologies Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC), a reciprocal insurer that partners with hospital associations to provide various types of coverage to healthcare providers and systems.
This new agreement provides educational resources and programs to MHA members on best practices in blood culture collection and the role of clinically proven solutions, including Steripath, in virtually eliminating blood culture contamination at the source. Two MHA member hospitals have also been selected to participate in a pilot program, sponsored by the HPIC, to measure the impact Steripath has on reducing blood culture contamination. One of the primary goals of the pilot is to establish a standardized blood culture collection and contamination prevention model that may be followed by other MHA members to further increase patient safety and outcomes across the State of Mississippi. MHA Solutions and Magnolia Medical will also be sponsoring roundtable symposiums with C-suite executives from MHA member hospitals on the national movement to a new 1% or below blood culture contamination rate, a significant reduction from the current national target benchmark of 3%. Blood culture is the gold standard for detecting blood stream infections, including sepsis. An estimated 58 million are performed each year.2 A reduction in blood culture contamination rate from 3% to 1% equates to approximately 1.2 million fewer patients impacted by a potential misdiagnosis of sepsis. “The goal of MHA Solutions is to provide the best products and services possible for our members and clients,” said Eddie Foster, President and CEO of MHA Solutions. “Steripath, with its clinically proven results, aligns with our goal. We are excited to join Magnolia Medical in advancing to a higher standard of care for sepsis diagnostic accuracy by providing new technology solutions and practice change to our members that can prevent patient harm due to false-positive blood cultures. We look forward to sharing the results of the HPIC-sponsored Steripath pilot with our membership of over 100 hospitals.” “Educating on best practices that can enable elimination of blood culture contamination and support the national movement to a 1% blood culture contamination rate is our core focus as a company,” said Greg Bullington, CEO of Magnolia Medical. “We are pleased to collaborate with MHA Solutions, the Mississippi Hospital Association, and HPIC to further improve patient safety and outcomes at hospitals throughout Mississippi. By increasing awareness of clinically proven technology solutions coupled with best practice educational strategies, our collective goal is to support MHA members in achieving a better standard for their patients.” Blood cultures tests are an essential tool used to diagnose bloodstream infections, including sepsis, to determine the specific pathogen causing the infection, and target appropriate antimicrobial therapy to treat the patient. The problem with the test lies within the collection process. During venipuncture, skin fragments containing viable microorganisms are often dislodged and collected with the blood specimen. These organisms can contaminate the sample and cause the patient to receive a false-positive result. Decades of research shows that false-positive blood culture results routinely lead to unnecessary and prolonged use of broad-spectrum antibiotics, which can have significant downstream clinical and cost consequences. Steripath, a sterile vein-to-bottle or vein-to-syringe closed-system device, addresses the issue by diverting and sequestering skin microbes that most commonly cause contamination, helping to ensure specimen integrity and accurate test results. Steripath has demonstrated clinical and cost-effectiveness in 20 studies, including 7 peer-reviewed publications. Results have demonstrated sustained zero or near-zero blood culture contamination rates, up to a 31% reduction in vancomycin days of therapy, and up to a 12-fold decrease in false-positive CLABSIs.3-10 This data demonstrating the clinical performance of Steripath affirms that patient harm resulting from false-positive sepsis diagnoses can be prevented. About Magnolia Medical About MHA Solutions About HPIC References:
SOURCE Magnolia Medical Technologies |
View original content to download multimedia:
